Literature DB >> 28759367

A step towards predicting checkpoint inhibitor response in kidney cancer.

Manuel Caitano Maia1, Eddy S Yang2, Neeraj Agarwal3, Sumanta K Pal4.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28759367     DOI： 10.1016/S1470-2045(17)30533-8

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  1 in total

1.  Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial.

Authors:  Thomas Powles; Michael B Atkins; Bernard Escudier; Robert J Motzer; Brian I Rini; Lawrence Fong; Richard W Joseph; Sumanta K Pal; Mario Sznol; John Hainsworth; Walter M Stadler; Thomas E Hutson; Alain Ravaud; Sergio Bracarda; Cristina Suarez; Toni K Choueiri; James Reeves; Allen Cohn; Beiying Ding; Ning Leng; Kenji Hashimoto; Mahrukh Huseni; Christina Schiff; David F McDermott
Journal:  Eur Urol       Date:  2021-03-05       Impact factor: 24.267
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.